Larimar Therapeutics, Inc. (LRMR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Bala Cynwyd, PA, 미국. 현재 CEO는 Carole S. Ben-Maimon.
LRMR 을(를) 보유 IPO 날짜 2014-06-19, 65 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $416.77M.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
